Growing market for ROS1 inhibitors driven by new therapies
The market for ROS1 inhibitors, targeted treatments primarily used in non-small cell lung cancer (NSCLC), is set to see significant growth as novel therapies gain traction and a precision medicine approach reshapes the oncology landscape.
According to a new report from DelveInsight, the market size across the USA, Europe, and Japan was approximately $290 million in 2023, with the USA representing the largest share.
Xalkori (crizotinib), the leading ROS1 inhibitor in the USA, has been widely prescribed for NSCLC but may see a decline in market dominance by 2034 as new-generation therapies emerge.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze